Treatment with ACE inhibitors or ARBs and risk of severe/lethal COVID-19: a meta-analysis.

Maria Elena FlaccoCecilia Acuti MartellucciFrancesca BraviGiustino ParrutiRosaria CappadonaAlfonso MascitelliRoberto ManfrediniLorenzo G MantovaniLamberto Manzoli

Published in: Heart (British Cardiac Society) (2020)

The present meta-analysis strongly supports the recommendation of several scientific societies to continue ARBs or ACE inhibitors for all patients, unless otherwise advised by their physicians who should thus be reassured.

Keyphrases

systematic review
end stage renal disease
coronavirus disease
sars cov
primary care
newly diagnosed
ejection fraction
chronic kidney disease
angiotensin ii
angiotensin converting enzyme
peritoneal dialysis
early onset
meta analyses
patient reported
respiratory syndrome coronavirus